Effettuare il login Iscriviti gratis

Adma Biologics Inc Avanti P/E

Cos'è Avanti P/E di Adma Biologics Inc?

Avanti P/E di Adma Biologics Inc è -68.30

Qual è la definizione di Avanti P/E?



Il rapporto prezzo / utili a termine è il rapporto tra il prezzo delle azioni di una società e l'utile stimato per azione della società per i prossimi dodici mesi.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Avanti P/E di aziende nel Health Care settore su NASDAQ rispetto a Adma Biologics Inc

Cosa fa Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Aziende con avanti p/e simili a Adma Biologics Inc